Literature DB >> 31629037

Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide.

Yingshan Qiu1, Rico C H Man1, Qiuying Liao1, Keshia L K Kung1, Michael Y T Chow2, Jenny K W Lam3.   

Abstract

Pulmonary delivery of messenger RNA (mRNA) has considerable potential as therapy or vaccine for a range of lung diseases. Inhaled dry powder formulation of mRNA is particularly attractive as it has superior stability and dry powder inhaler is relatively easy to use. A safe and effective mRNA delivery vector as well as a suitable particle engineering method are required to produce a dry powder formulation that is respirable and mediates robust transfection in the lung. Here, we introduce a novel RNA delivery vector, PEG12KL4, in which the synthetic cationic KL4 peptide is attached to a monodisperse linear PEG of 12-mers. The PEG12KL4 formed nano-sized complexes with mRNA at 10:1 ratio (w/w) and mediated effective transfection on human lung epithelial cells. PEG12KL4/mRNA complexes were successfully formulated into dry powder by spray drying (SD) and spray freeze drying (SFD) techniques. Both SD and SFD powder exhibited satisfactory aerosol properties for inhalation. More importantly, the biological activity of the PEG12KL4 /mRNA complexes were successfully preserved after drying. Using luciferase mRNA, the intratracheal administration of the liquid or powder aerosol of PEG12KL4 /mRNA complexes at a dose of 5μg mRNA resulted in luciferase expression in the deep lung region of mice 24h post-transfection. The transfection efficiency was superior to naked mRNA or lipoplexes (Lipofectamine 2000), in which luciferase expression was weaker and restricted to the tracheal region only. There was no sign of inflammatory response or toxicity of the PEG12KL4 /mRNA complexes after single intratracheal administration. Overall, PEG12KL4 is an excellent mRNA transfection agent for pulmonary delivery. This is also the first study that successfully demonstrates the preparation of inhalable dry powder mRNA formulations with in vivo transfection efficiency, showing the great promise of PEG12KL4 peptide as a mRNA delivery vector candidate for clinical applications.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Inhalation; PEGylation; Peptide; Spray drying; Spray freeze drying; mRNA transfection

Year:  2019        PMID: 31629037     DOI: 10.1016/j.jconrel.2019.10.026

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  29 in total

1.  Formulation and Delivery Technologies for mRNA Vaccines.

Authors:  Chunxi Zeng; Chengxiang Zhang; Patrick G Walker; Yizhou Dong
Journal:  Curr Top Microbiol Immunol       Date:  2020-06-02       Impact factor: 4.291

2.  Spray-Dried and Spray-Freeze-Dried Powder Formulations of an Anti-Interleukin-4Rα Antibody for Pulmonary Delivery.

Authors:  Harry W Pan; Han Cong Seow; Jason C K Lo; Jinlin Guo; Lingqiao Zhu; Susan W S Leung; Chenghai Zhang; Jenny K W Lam
Journal:  Pharm Res       Date:  2022-07-25       Impact factor: 4.580

Review 3.  mRNA-based therapeutics: powerful and versatile tools to combat diseases.

Authors:  Shugang Qin; Xiaoshan Tang; Yuting Chen; Kepan Chen; Na Fan; Wen Xiao; Qian Zheng; Guohong Li; Yuqing Teng; Min Wu; Xiangrong Song
Journal:  Signal Transduct Target Ther       Date:  2022-05-21

Review 4.  Mucosal vaccine delivery: A focus on the breakthrough of specific barriers.

Authors:  Mengwen Huang; Miaomiao Zhang; Hongbin Zhu; Xiaojiao Du; Jun Wang
Journal:  Acta Pharm Sin B       Date:  2022-07-06       Impact factor: 14.903

Review 5.  Inhalable mRNA vaccines for respiratory diseases: a roadmap.

Authors:  Esther H Roh; Catherine A Fromen; Millicent O Sullivan
Journal:  Curr Opin Biotechnol       Date:  2021-12-08       Impact factor: 10.279

Review 6.  Strategies to deliver RNA by nanoparticles for therapeutic potential.

Authors:  Alysia Cox; Siyoung A Lim; Eun Ji Chung
Journal:  Mol Aspects Med       Date:  2021-08-05

Review 7.  mRNA vaccine: a potential therapeutic strategy.

Authors:  Yang Wang; Ziqi Zhang; Jingwen Luo; Xuejiao Han; Yuquan Wei; Xiawei Wei
Journal:  Mol Cancer       Date:  2021-02-16       Impact factor: 27.401

Review 8.  Optimizations of In Vitro Mucus and Cell Culture Models to Better Predict In Vivo Gene Transfer in Pathological Lung Respiratory Airways: Cystic Fibrosis as an Example.

Authors:  Rosy Ghanem; Véronique Laurent; Philippe Roquefort; Tanguy Haute; Sophie Ramel; Tony Le Gall; Thierry Aubry; Tristan Montier
Journal:  Pharmaceutics       Date:  2020-12-31       Impact factor: 6.321

Review 9.  Inhalation delivery technology for genome-editing of respiratory diseases.

Authors:  Michael Y T Chow; Rachel Yoon Kyung Chang; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2020-06-05       Impact factor: 15.470

Review 10.  Inhaled RNA Therapy: From Promise to Reality.

Authors:  Michael Y T Chow; Yingshan Qiu; Jenny K W Lam
Journal:  Trends Pharmacol Sci       Date:  2020-09-04       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.